Chu Limoges
Limoges, 87042, France
Location status: Recruiting
NCT Number: NCT07295808
IgA nephropathy (IgA Nephropathy), or Berger's disease, is the most common form of primary glomerulonephritis. It is a major cause of end-stage renal failure, often leading to dialysis or kidney transplantation. Recurrence is common after transplantation, compromising graft survival. Rheumatoid purpura (or IgA vasculitis) shares a common pathophysiology with IgA N, characterised by mesangial deposits containing IgA-rich immune complexes, but differs in its systemic involvement (skin, joints and digestive system).
In terms of pathophysiology, the histological signature of these conditions is based on the accumulation of abnormal IgA within the glomerulus. The mechanisms responsible for the nephrotoxicity of these IgA remain partially unclear. In patients with NIgA, several qualitative abnormalities of IgA have been well described, including a glycosylation defect that promotes IgA polymerisation and the emergence of anti-IgA autoantibodies. These immune complexes, found in glomerular deposits, induce a local inflammatory reaction. Experimental work conducted on mouse models developed at the CRIBL laboratory has shown that these abnormalities may be linked to a dysregulation of the immune response, leading to the production of IgA with physicochemical properties that promote their deposition in the kidney.
However, the location of nephritogenic IgA-secreting B cells remains poorly understood. Recent data suggest that this production could occur directly within the renal parenchyma, where activated B lymphocytes would locally produce pathogenic IgA. Following on from these observations, our study aims to characterise the immunoglobulin (Ig) repertoires in patients with IgA nephropathy, particularly those from renal lymphoid infiltrates, and to compare them with the repertoires of circulating B cells.
We hypothesise that certain sequence motifs within the variable domains of IgA, particularly the CDR3 regions, could constitute specific biomarkers of NIgA. Their detection in peripheral blood could enable non-invasive or predictive diagnosis, complementing the renal biopsy that is currently essential.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Limoges, 87042, France
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood sample taken in a Tempus tube during a blood test performed at the same time as the kidney biopsy.
Time frame: 6 months
Describe the repertoire of variable domains of IgA with nephritogenic potential in patients with IgA nephropathies
Time frame: 6 months
Search circulating repertoires, based on a blood sample taken at the time of diagnosis and at the same time as the renal biopsy, for the presence of nephritogenic IgA previously identified using the renal Ig repertoire.
Contact information is provided by the study sponsor or research team.
University Hospital, Limoges
Other
Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies
Acronym: Rep-IgAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001979
Chronic Disease, Disease Attributes
Bethesda, Maryland, United States
View Trial DetailsNCT06963827
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Birmingham, Alabama, United States
View Trial DetailsNCT07678073
Chronic Disease, Disease Attributes
Gaziantep, State/Province, Turkey (Türkiye)
View Trial DetailsNCT07572890
CKD, Chronic Disease
Winter Park, Florida, United States
View Trial Details